• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale Health

0.82 EUR-0.24 %24.7, 17.29
4,755 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-0.24 %
+0.49 %
-33.01 %
-55.84 %
-59.80 %
-67.43 %
-3.96 %
-84.96 %
-84.00 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
50.21M EUR
Turnover
47.89K EUR
P/E (adj.) (26e)
-2.87
EV/EBIT (adj.) (26e)
-0.57
P/B (26e)
0.97
EV/S (26e)
1.73
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
1.40 EUR
Updated
11.06.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 12.06.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
It seems that the Swedish telehealth company Supernormal uses Nightingale’s blood test as part of providing its services. According to their website, the company has over 10,000 customers. Blood samples are apparently taken at partner clinics throughout Sweden. Otherwise, the service...
14 hours ago
by The Ugly Buckling
9
Do you have any actual, substantive criticism to offer as well? A new person who comes to the forum to showcase their own brilliance and educational background without providing any other content is, by definition, a so-called spammer. Best regards, a layperson shareholder of Nightingale...
7/11/2026, 7:45 PM
by Farseer
8
Yu Kato started as the Commercial Director for Nightingale’s research sales in Japan in June. Kato moves to the position from Olink Proteomics, where he held the role of Business Development Manager. Source: A little belated, but I’m happy to share that I joined Nightingale Health...
14 hours ago
by The Ugly Buckling
7
Nightingale now has two commercial directors in Japan. In addition, Kyoko Harimoto will join from August 2025. There has been no progress in Japan (at least to an outsider’s eye) for many years, so we are waiting for results. PS. There was a Finn there at one point, I wonder what...
14 hours ago
by Monsieur
5
I’ve been thinking about your point regarding my AI outputs being seen as “AI ads.” Admittedly, the tone has been sales-oriented, which can be annoying. I have now created a test version of the analysis based on the “cancer article.” The source is the same article published in Nature...
7/15/2026, 9:41 AM
by The Ugly Buckling
5
Interesting piece of information. In South Savo, they are implementing NG technology on several fronts. Time to put the results on the table and become a key player in the EU’s Safe Heart plan… Here is also a link to those prevention goals in the EU: Public Health Cardiovascular ...
7/15/2026, 8:46 AM
by Cle
5
The website kukaomistaa.fi, through which you can view information about the owners of companies listed on the Helsinki Stock Exchange. You might get a bit more information from there compared to Nightingale’s own list of owners. At the very least, there is more information available...
7/18/2026, 5:49 PM
by The Ugly Buckling
4
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.9
2026

Annual report '26

5.11
2026

General meeting '26

9.3
2027

Interim report Q2'27

Press release01.07.2026, 15.00

Nightingale Health and Archipelago Health partner to bring preventive screening to small-island health systems in the Crown Dependencies, Bermuda and the Caribbean

Nightingale Health
Regulatory press release29.06.2026, 17.15

Nightingale Health’s Board of Directors resolved on new stock option program

Nightingale Health
Nightingale: We factored the project delay into our estimates
Research12.06.2026, 09.20 by
Antti Siltanen, Antti Luiro

Nightingale: We factored the project delay into our estimates

The revenue outlook for the next fiscal year exceeds 10 MEUR.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nightingale's profit warning: Project delay shifts revenue to next year
Analyst Comment09.06.2026, 08.40 by
Antti Siltanen

Nightingale's profit warning: Project delay shifts revenue to next year

The company's business appears to be progressing in line with our estimates.

Nightingale Health
Regulatory press release08.06.2026, 18.25

Inside information, profit warning: Nightingale Health continues to grow but will not reach its 50% growth target this financial year as about EUR 2 million of revenue shifts to next financial year

Nightingale Health
Nightingale: Nightingale sings to a deaf market
Research04.06.2026, 08.36 by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
Nightingale joins wellbeing services county research project
Analyst Comment29.05.2026, 08.46 by
Antti Siltanen

Nightingale joins wellbeing services county research project

Nightingale's risk screening selects participants for lifestyle coaching.

Nightingale Health
Press release28.05.2026, 10.00

Nightingale Health joins South Savo Wellbeing Services County's preventive healthcare research project in Finland

Nightingale Health
Regulatory press release27.05.2026, 15.45

Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2026–2027

Nightingale Health
New partnership for Nightingale
Analyst Comment25.05.2026, 08.11 by
Antti Siltanen

New partnership for Nightingale

The new memorandum of understanding will expand blood analysis to the longevity programs in Switzerland and South Africa as early as this summer.

Nightingale Health
Press release22.05.2026, 08.30

Nightingale Health and Formula 100 Health partner in preventive health: Embedding multi-disease risk detection across longevity programmes in Switzerland and South Africa

Nightingale Health
Regulatory press release21.05.2026, 16.25

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health
Regulatory press release18.05.2026, 12.02

Nightingale Health Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Nightingale Health
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026, 11.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Nightingale H1'26: Research projects accelerate H2
Research06.03.2026, 10.44 by
Antti Siltanen

Nightingale H1'26: Research projects accelerate H2

Nightingale's major research projects will generate revenue in H2.

Nightingale Health
Nightingale, Webcast, Half-year financial report 1 July–31 December 2025
Webcast05.03.2026, 13.00

Nightingale, Webcast, Half-year financial report 1 July–31 December 2025

Nightingale Health
Regulatory press release05.03.2026, 08.00

Nightingale Health's half-year report: Delivering clinical value for healthcare and moving toward 50% revenue growth, supported by a strong sales pipeline

Nightingale Health
Nightingale H1'26 preview: Revenue still relies on research projects
Analyst Comment03.03.2026, 08.11 by
Antti Siltanen

Nightingale H1'26 preview: Revenue still relies on research projects

We expect revenue to grow, driven by research projects and the Terveystalo collaboration.

Nightingale Health
A step forward for Nightingale in New York
Analyst Comment10.02.2026, 07.50 by
Antti Siltanen

A step forward for Nightingale in New York

The New York laboratory permit allows tests to be offered to healthcare providers without separate FDA approval.

Nightingale Health
Regulatory press release09.02.2026, 20.30

Inside information: Nightingale Health achieves major milestone in the United States: New York laboratory now holds a clinical laboratory permit from New York State

Nightingale Health